T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Olema Pharmaceuticals
OLMA
$1.05B
| $17.6M | ﹤0.01% |
1,182,836
+86,801
| +8% | +$1.93M |
|
1077
Tetra Tech
TTEK
$8.28B
| $17.6M | ﹤0.01% |
584,462
+170,939
| +41% | +$6.04M |
|
1078
Commault Systems
CVLT
$6.19B
| $17.5M | ﹤0.01% |
224,208
-183,154
| -45% | -$17.4M |
|
1079
Globant
GLOB
$1.41B
| $17.4M | ﹤0.01% |
377,172
-18,549
| -5% | -$1.03M |
|
1080
McGrath RentCorp
MGRC
$2.95B
| $17.4M | ﹤0.01% |
157,625
+3,960
| +3% | +$440K |
|
1081
nLIGHT
LASR
$3.82B
| $17.3M | ﹤0.01% |
304,149
+277,575
| +1,045% | +$15M |
|
|
NBIS
1082
Nebius Group N.V.
NBIS
$47.7B
| $17.1M | ﹤0.01% |
164,821
-7,743
| -4% | -$773K |
|
1083
Pinnacle West Capital
PNW
$12.8B
| $16.9M | ﹤0.01% |
168,173
-2,046
| -1% | -$197K |
|
1084
Ultragenyx Pharmaceutical
RARE
$2.65B
| $16.8M | ﹤0.01% |
804,109
-750,257
| -48% | -$16.9M |
|
1085
RB Global
RBA
$21.7B
| $16.8M | ﹤0.01% |
175,513
+17,546
| +11% | +$1.86M |
|
1086
Align Technology
ALGN
$12B
| $16.8M | ﹤0.01% |
97,823
-1,131
| -1% | -$198K |
|
1087
Halozyme
HALO
$9.66B
| $16.8M | ﹤0.01% |
259,390
+17,352
| +7% | +$1.22M |
|
1088
Fox Class A
FOXA
$23.8B
| $16.7M | ﹤0.01% |
286,470
-21,646
| -7% | -$1.38M |
|
1089
Chewy
CHWY
$8.93B
| $16.7M | ﹤0.01% |
618,346
+436,043
| +239% | +$12.2M |
|
1090
Healthpeak Properties
DOC
$15.5B
| $16.5M | ﹤0.01% |
1,005,724
-11,769
| -1% | -$202K |
|
1091
Oshkosh
OSK
$9.66B
| $16.5M | ﹤0.01% |
112,059
+14,033
| +14% | +$2.19M |
|
1092
Unum
UNM
$13.8B
| $16.5M | ﹤0.01% |
225,826
+23,840
| +12% | +$1.78M |
|
1093
First Citizens BancShares
FCNCA
$24.3B
| $16.5M | ﹤0.01% |
8,744
+630
| +8% | +$1.26M |
|
1094
Hancock Whitney
HWC
$6.07B
| $16.4M | ﹤0.01% |
258,324
+46,110
| +22% | +$3.09M |
|
1095
Jack Henry & Associates
JKHY
$10.9B
| $16.4M | ﹤0.01% |
103,779
-170
| -0.2% | -$29.1K |
|
1096
Gartner
IT
$9.87B
| $16.3M | ﹤0.01% |
102,822
-90,049
| -47% | -$16.6M |
|
1097
Ingredion
INGR
$6.4B
| $16.3M | ﹤0.01% |
144,391
+7,827
| +6% | +$899K |
|
1098
SiriusPoint
SPNT
$3.01B
| $16.1M | ﹤0.01% |
749,298
+534,861
| +249% | +$11M |
|
1099
Super Micro Computer
SMCI
$19.3B
| $16.1M | ﹤0.01% |
706,168
-18,087
| -2% | -$543K |
|
1100
Plexus
PLXS
$6.78B
| $16M | ﹤0.01% |
78,823
+53,269
| +208% | +$10.1M |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.